Search

Vaxcyte Inc

Atvērts

SektorsVeselības aprūpe

58.03 -1.01

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

56.95

Max

60.14

Galvenie mērījumi

By Trading Economics

Ienākumi

-284M

-605M

EPS

-1.97

Darbinieki

507

EBITDA

22M

-292M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+94.24% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 2. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

944M

8.7B

Iepriekšējā atvēršanas cena

59.04

Iepriekšējā slēgšanas cena

58.03

Ziņu noskaņojums

By Acuity

50%

50%

171 / 340 Rangs Healthcare

Vaxcyte Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. aug. 19:46 UTC

Vaxcyte Inc shares are higher today, supported by broader market gains following positive sentiment from the recent inflation report. The stock remains above its 20-day moving average.

2026. g. 11. aug. 23:11 UTC

Vaxcyte Inc shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the price action.

2026. g. 10. aug. 19:56 UTC

Vaxcyte Inc shares are higher, continuing gains since Friday's close, reaching a peak earlier in the session. No specific news was identified for the move.

2026. g. 7. aug. 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

2026. g. 6. aug. 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

2026. g. 5. aug. 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

2026. g. 4. aug. 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

2026. g. 3. aug. 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

2026. g. 31. jūl. 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

2026. g. 30. jūl. 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

2026. g. 29. jūl. 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

2026. g. 28. jūl. 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

2026. g. 27. jūl. 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

2026. g. 23. jūl. 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

2026. g. 21. jūl. 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Salīdzinājums

Cenas izmaiņa

Vaxcyte Inc Prognoze

Cenas mērķis

By TipRanks

94.24% augšup

Prognoze 12 mēnešiem

Vidējais 114.33 USD  94.24%

Augstākais 163 USD

Zemākais 75 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Vaxcyte Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

171 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
help-icon Live chat